India, March 13 -- image credit- shutterstock

Raichur-basedShilpa Medicare Limited, a leading API and formulation manufacturer, has announced that the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) has approved its Investigational New Drug (IND) - Nor Ursodeoxycholic Acid (Nor UDCA) Tablets 500 mg - and recommended marketing authorisation for treating non-alcoholic fatty liver disease (NAFLD).

NAFLD, the most prevalent liver disease, affects approximately 25% of the global population (1.2 billion people), including 188 million inIndia. Left untreated, NAFLD can progress to non-alcoholic steatohepatitis (NASH), a severe and potentially fatal condition.

Shilpa Medicare had earlier completed phas...